AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

It is possible to successfully manage and control the symptoms of atopic dermatitis with proper treatment and precautions. Treatment options typically include using moisturisers to keep the skin ...

STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis (AD) and potentially other ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in ...

The celebrity dermatologist talks about finding her moment of clarity in finding relief for her eczema symptoms and how she ...

“As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for the treatment of atopic dermatitis,” said Richard A ...

Atopic dermatitis, or eczema ... but various treatments may help. Home remedies may help manage symptoms of dermatitis. Thse include avoiding known triggers, moisturizing the skin, and avoiding ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.

Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...